Dr. Aslam Ejaz, MD
Claim this profileOhio State University Comprehensive Cancer Center
Studies Thyroid Cancer
Studies Stomach Cancer
6 reported clinical trials
14 drugs studied
Affiliated Hospitals
Clinical Trials Aslam Ejaz, MD is currently running
Nivolumab +/− Relatlimab
for Liver Cancer
The purpose of this study is to determine the safety and tolerability of neoadjuvant/adjuvant Nivolumab or Nivolumab plus Relatlimab in patients with HCC.
Recruiting1 award Phase 112 criteria
Ablative Therapy + Systemic Therapy
for Colorectal Cancer
This phase III trial compares total ablative therapy and usual systemic therapy to usual systemic therapy alone in treating patients with colorectal cancer that has spread to up to 4 body sites (limited metastatic). The usual approach for patients who are not participating in a study is treatment with intravenous (IV) (through a vein) and/or oral medications (systemic therapy) to help stop the cancer sites from getting larger and the spread of the cancer to additional body sites. Ablative means that the intention of the local treatment is to eliminate the cancer at that metastatic site. The ablative local therapy will consist of very focused, intensive radiotherapy called stereotactic ablative radiotherapy (SABR) with or without surgical resection and/or microwave ablation, which is a procedure where a needle is temporarily inserted in the tumor and heat is used to destroy the cancer cells. SABR, surgical resection, and microwave ablation have been tested for safety, but it is not scientifically proven that the addition of these treatments are beneficial for your stage of cancer. The addition of ablative local therapy to all known metastatic sites to the usual approach of systemic therapy could shrink or remove the tumor(s) or prevent the tumor(s) from returning.
Recruiting2 awards Phase 3
More about Aslam Ejaz, MD
Clinical Trial Related4 years of experience running clinical trials · Led 6 trials as a Principal Investigator · 3 Active Clinical TrialsTreatments Aslam Ejaz, MD has experience with
- Questionnaire Administration
- Resection
- Best Practice
- Exercise Intervention
- Physical Therapy
- Anesthesia Procedure
Breakdown of trials Aslam Ejaz, MD has run
Thyroid Cancer
Stomach Cancer
Hepatocellular Carcinoma
Gastric Cancer
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does Aslam Ejaz, MD specialize in?
Aslam Ejaz, MD focuses on Thyroid Cancer and Stomach Cancer. In particular, much of their work with Thyroid Cancer has involved treating patients, or patients who are undergoing treatment.
Is Aslam Ejaz, MD currently recruiting for clinical trials?
Yes, Aslam Ejaz, MD is currently recruiting for 2 clinical trials in Columbus Ohio. If you're interested in participating, you should apply.
Are there any treatments that Aslam Ejaz, MD has studied deeply?
Yes, Aslam Ejaz, MD has studied treatments such as Questionnaire Administration, Resection, Best Practice.
What is the best way to schedule an appointment with Aslam Ejaz, MD?
Apply for one of the trials that Aslam Ejaz, MD is conducting.
What is the office address of Aslam Ejaz, MD?
The office of Aslam Ejaz, MD is located at: Ohio State University Comprehensive Cancer Center, Columbus, Ohio 43210 United States. This is the address for their practice at the Ohio State University Comprehensive Cancer Center.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.